Displaying drugs 10851 - 10875 of 11614 in total
EP-2104R
EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.
Investigational
LGD2941
LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
Investigational
Matched Description: … LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand …
Repinotan
Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Investigational
Matched Description: … Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective …
Flumequine
Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.
Withdrawn
Matched Description: … Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat …
Concizumab
Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
Investigational
Matched Description: … Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder …
Clorindione
Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans.
Experimental
Matched Description: … Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans. …
GsMtx-4
GsMtx-4 is a peptide found in tarantula venom that inhibits mechanosensitive ion channel (MSC) activity.
Investigational
Matched Description: … GsMtx-4 is a peptide found in tarantula venom that inhibits mechanosensitive ion channel (MSC) activity …
GIVI-MPC
GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.
Investigational
Matched Description: … GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells …
P-42 peptide
P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein
Investigational
Matched Description: … P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin …
Ethylmorphine
A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and...
Experimental
Illicit
Matched Description: … A narcotic analgesic and antitussive. ... In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products). …
JB991
JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. The drug exerts marked antiproliferative and pro-apoptotic effect in human keratinocytes and fibroblasts in vitro. In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug...
Investigational
Matched Description: … JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. ... In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth ... VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway …
N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide
N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide is a solid. This compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5.
Experimental
Matched Description: … N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide is a solid ... This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5. …
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. Known drug targets of 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole include genome polyprotein.
Experimental
Matched Description: … 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole is a solid. ... These are aromatic compounds containing an ether group substituted with a benzene ring. …
Cixutumumab
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of...
Investigational
Matched Description: … IGF-IR is overexpressed in a variety of tumour types. ... Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like …
Taspoglutide
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no...
Investigational
Matched Description: … Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation …
Lecithin, soybean
A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as 1,2-diacyl-3-phosphocholines. Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk. The emulsifying and surfactant properties are useful in food additives and...
Experimental
Matched Description: … Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk. ... A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines …
V591
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … vaccine virus as a vector for COVID-19 antigen delivery[L30593]. ... The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles …
MB07811
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
Matched Description: … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower ... MB07811, a small molecule that is administered orally, has been extensively studied preclinically and ... MB07811 combines a novel thyroid hormone receptor agonist with the Company's novel HepDirect liver targeting …
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Matched Description: … Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a ... pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a ... These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, …
GFT14
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.
GFT14 is destined to improve the condition of patients at risk from cardiovascular disease...
Investigational
Matched Description: … GFT14 is a new class of medicaction for treatment of cardiometabolic disease. ... GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous …
Posizolid
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
OPC-28326
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being...
Investigational
Sulfatide
Any of a class of cerebroside sulfuric esters, they are found largely in the medullated nerve fibers and may accumulate in metachromatic leukodystrophy.
Experimental
Matched Description: … Any of a class of cerebroside sulfuric esters, they are found largely in the medullated nerve fibers …
Lemuteporfin
Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
Investigational
Matched Description: … Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer …
Displaying drugs 10851 - 10875 of 11614 in total